Research
Abstract

Latest epidemiological studies suggest a role of  vasopressin in the pathogenesis of diabetes mellitus and metabolic disorders via activation of hepatic V1a and/or pancreatic islet V1b receptors. The first part of this lecture will describe the adverse effects of vasopressin, as revealed by clinical and experimental studies in kidney diseases, hypertension, diabetes and the metabolic syndrome. The second part will provide insights into vasopressin physiology and pathophysiology that may be relevant to the understanding of these adverse effects and that are linked to the excretion of concentrated nitrogen wastes and associated hyperfiltration.

Publications

Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention and retardation of kidney disease? (Invited review) Nature reviews Nephrology 9(4):223-39. 2013

Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L: Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J. Am. Soc. Nephrol. 19: 1721–1731, 2008

Burnier M, Murielle Bochud M, Bankir L: Response to "Nocturnal Blood Pressure Fall Changes in Correlation With Urinary Sodium Excretion". Hypertension, 52: e11. Aug 2008